

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
August 04, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

August 04, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b): 82-\_\_\_\_\_

TRANSACTION IN OWN SHARES

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

## Edgar Filing: NOVO NORDISK A S - Form 6-K

On 29 January 2009, Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 27 July 2009, the following transactions have been made under the programme:

	NUMBER OF SHARES	AVERAGE PURCHASE PRICE	TRANSACTION VALUE, DKK
ACCUMULATED, LAST ANNOUNCEMENT	9,950,382		2,778,221,354
27 July 2009	75,000	304.9250	22,869,375
28 July 2009	95,000	312.0840	29,647,980
29 July 2009	149,500	305.6500	45,694,675
30 July 2009	85,000	307.7800	26,161,300
31 July 2009	85,000	307.2900	26,119,650
ACCUMULATED UNDER THE PROGRAMME	10,439,882		2,928,714,334

With the transactions stated above, Novo Nordisk owns a total of 21,231,941 treasury shares, corresponding to 3.4% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

Further information:

Media:

Outside North America:

Elin K Hansen  
Tel: (+45) 4442 3450  
[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

In North America:

Sean Clements  
Tel: (+1) 609 514 8316  
[secl@novonordisk.com](mailto:secl@novonordisk.com)

Investors:

Outside North America:

Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

In North America:

Hans Rommer  
Tel: (+1) 609 919 7937  
[hrrm@novonordisk.com](mailto:hrrm@novonordisk.com)

Company Announcement no 45 / 2009

SIGNATURES

## Edgar Filing: NOVO NORDISK A S - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 04, 2009

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer